Scarica l'app Stockscreener
51.61
4.25%
-2.29
Dopo l'orario di chiusura:
51.53
-0.08
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bio Techne Corp Borsa (TECH) Ultime notizie
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know - Yahoo Finance
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 - The Malaysian Reserve
Bio-Techne to Showcase Next-Generation Solutions for Gene and Ce - GuruFocus
When the Price of (TECH) Talks, People Listen - news.stocktradersdaily.com
Bio-Techne (TECH) Target Price Lowered to $70 by UBS Analyst | T - GuruFocus
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating - marketscreener.com
Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance - MSN
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - GuruFocus
Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow - TipRanks
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Sto - GuruFocus
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus
Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com
Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus
BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - StreetInsider
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Eng - GuruFocus
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing | TECH Stock News - GuruFocus
Bio-Techne price target lowered to $63 from $72 at RBC Capital - TipRanks
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - Stock Titan
Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne Third Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference | TECH Stock News - GuruFocus
RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating - marketscreener.com
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... - Yahoo Finance
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global Challenges - GuruFocus
Bio-Techne Reports Strong Q3 2025 Revenue Growth - TipRanks
Bio-Techne Q3 2025 Earnings Call Transcript - MarketBeat
Bio-Techne’s Earnings Call: Growth Amid Challenges - TipRanks
Revolutionizing Gene Therapy Protein Expression Potency Assays - Genetic Engineering and Biotechnology News
Bio-Techne Leads Key Proteomic Reagent Markets - Morningstar
Bio-Techne exceeds profit expectations, announces new share buyback plan - MSN
Bio-Techne reports Q3 adjusted EPS 56c, consensus 51c - TipRanks
Bio-Techne’s Resilience and Strong Financial Performance Justify Buy Rating Amid Market Challenges - TipRanks
Earnings call transcript: Bio-Techne beats Q3 2025 EPS forecasts, stock dips - Investing.com Nigeria
Evercore ISI Cuts Price Target on Bio-Techne to $60 From $70 - marketscreener.com
U.S. STOCKS ON THE MOVE-Bio-Techne, Johnson Controls, Tempus AI - TradingView
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket - Zacks Investment Research
Bio Techne (TECH) Fell on Negative Funding Environment - Insider Monkey
Is the Options Market Predicting a Spike in BioTechne Stock? - Zacks Investment Research
Bio-Techne Shares Slide Amid Valuation Concerns - TipRanks
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2025, Payable on May 30, 2025 - marketscreener.com
Bio-Techne shares surges nearly 6% on earnings beat, strong guidance - Investing.com Nigeria
Bio-Techne shares surges nearly 6% on earnings beat, strong guidance By Investing.com - Investing.com South Africa
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS | TECH Sto - GuruFocus
Bio-Techne Board Approves Share Repurchase Program - Nasdaq
Bio-Techne Reports Q3 2025 Financial Results - TipRanks
Bio-Techne Corporation (TECH) Announces $500 Million Share Repurchase Program - GuruFocus
Bio-Techne Corp (TECH) Q3 Earnings: Adjusted EPS Surpasses Estimates at $0.56, Revenue Slightly Misses at $316.2 Million - GuruFocus
Bio-Techne earnings beat by $0.05, revenue fell short of estimates - Investing.com South Africa
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM | TECH Stock News - GuruFocus
Bio-Techne (NASDAQ:TECH) Posts Q1 Sales In Line With Estimates, Stock Soars - Yahoo Finance
Bio-Techne Corp. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Bio-Techne Declares Dividend And New Share Repurchase Program - TradingView
Bio-Techne Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2025 - marketscreener.com
Bio-Techne Earnings: Strong Growth in Protein Sciences, but US Academic Market Uncertain - Morningstar
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):